BIOMAT Database Logo BIOMAT Database Logo

Effects of transdermal and oral estrogen supplementation on endothelial function, inflammation and cellular redox state. 2003

H Kawano, and H Yasue, and N Hirai, and T Yoshida, and H Fukushima, and S Miyamoto, and S Kojima, and J Hokamaki, and H Nakamura, and J Yodoi, and H Ogawa
Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Kumamoto, Japan. koumei@gpo.kumamoto-u.ac.jp

The incidence of ischemic heart disease shows a sharp rise after menopause. However, the effects of hormone replacement therapy (HRT) on cardiovascular disease are still controversial. Not only oxidative stress, but also inflammation has been suggested to play an important role in the pathogenesis of cardiovascular events. We compared the effects of HRT on endothelial function, cellular antioxidant system and inflammation between oral and transdermal administration in mild hypercholesterolemic postmenopausal women. Transdermal estradiol replacement was administrated to 12 patients (mean age 53 years) for 12 weeks, and oral conjugated equine estrogen was administrated to 12 patients (mean age 54 years) for 12 weeks. The flow-mediated endothelium-dependent dilation of the brachial artery, serum levels of thioredoxin as a marker of the cytoprotective antioxidant system, and high-sensitivity C-reactive protein (hs-CRP) were measured every 4 weeks. The flow-mediated vasodilation increased with HRT (oral, baseline 4.9 +/- 0.5, 4-week 8.9 +/- 0.7*, 8-week 9.9 +/- 0.6*, 12-week 9.4 +/- 0.7*; transdermal, 4.7 +/- 0.6, 8.3 +/- 0.7*, 9.1 +/- 0.8*, 8.9 +/- 0.9%*, * = p < 0.01 versus baseline). The thioredoxin levels decreased with HRT (oral, 26.1 +/- 7.2, 24.1 +/- 8.2, 22.1 +/- 7.8, 19.1 +/- 7.0*; transdermal, 26.9 +/- 7.4, 23.4 +/- 8.7, 21.1 +/- 7.9, 19.2 +/- 7.2 ng/ml*, * = p < 0.01 versus baseline). There were no differences in the variation of the flow-mediated vasodilation or thioredoxin concentrations between the 2 groups. The hs-CRP levels increased with oral HRT (0.32 +/- 0.12, 0.72 +/- 0.17*, 0.86 +/- 0.23*, 0.88 +/- 0.21 mg/dl*, * = p < 0.01 versus baseline), while transdermal HRT did not elicit any changes (0.35 +/- 0.15, 0.34 +/- 0.17, 0.38 +/- 0.20, 0.36 +/- 0.22 mg/dl). The differences of hs-CRP concentrations between the 2 groups analyzed by 2-way ANOVA were significant (p < 0.01). Oral HRT instigated inflammation, but transdermal did not. Both oral and transdermal HRT, however, improved endothelial function and decreased oxidative stress through affecting the cellular redox state. These differentials in the effects caused by the course of administration may affect the future cardiovascular events.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D005640 Follicle Stimulating Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. FSH (Follicle Stimulating Hormone),Follicle-Stimulating Hormone,Follitropin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Kawano, and H Yasue, and N Hirai, and T Yoshida, and H Fukushima, and S Miyamoto, and S Kojima, and J Hokamaki, and H Nakamura, and J Yodoi, and H Ogawa
Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women.
November 2000, Circulation,
H Kawano, and H Yasue, and N Hirai, and T Yoshida, and H Fukushima, and S Miyamoto, and S Kojima, and J Hokamaki, and H Nakamura, and J Yodoi, and H Ogawa
Transdermal versus oral estrogen therapy in postmenopausal smokers: hemodynamic and endothelial effects.
January 2004, Obstetrics and gynecology,
H Kawano, and H Yasue, and N Hirai, and T Yoshida, and H Fukushima, and S Miyamoto, and S Kojima, and J Hokamaki, and H Nakamura, and J Yodoi, and H Ogawa
Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women.
October 2006, Human reproduction (Oxford, England),
H Kawano, and H Yasue, and N Hirai, and T Yoshida, and H Fukushima, and S Miyamoto, and S Kojima, and J Hokamaki, and H Nakamura, and J Yodoi, and H Ogawa
Effects of oral and transdermal estrogen replacement on migraine.
March 1999, Cephalalgia : an international journal of headache,
H Kawano, and H Yasue, and N Hirai, and T Yoshida, and H Fukushima, and S Miyamoto, and S Kojima, and J Hokamaki, and H Nakamura, and J Yodoi, and H Ogawa
Effects of oral and transdermal low-dose estrogen therapy on echocardiographic parameters of cardiac function.
September 2003, Fertility and sterility,
H Kawano, and H Yasue, and N Hirai, and T Yoshida, and H Fukushima, and S Miyamoto, and S Kojima, and J Hokamaki, and H Nakamura, and J Yodoi, and H Ogawa
Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins.
October 2006, Contraception,
H Kawano, and H Yasue, and N Hirai, and T Yoshida, and H Fukushima, and S Miyamoto, and S Kojima, and J Hokamaki, and H Nakamura, and J Yodoi, and H Ogawa
Cellular Senescence, Neurological Function, and Redox State.
June 2018, Antioxidants & redox signaling,
H Kawano, and H Yasue, and N Hirai, and T Yoshida, and H Fukushima, and S Miyamoto, and S Kojima, and J Hokamaki, and H Nakamura, and J Yodoi, and H Ogawa
Oral Administration of Glucosamine Improves Vascular Endothelial Function by Modulating Intracellular Redox State.
December 2017, International heart journal,
H Kawano, and H Yasue, and N Hirai, and T Yoshida, and H Fukushima, and S Miyamoto, and S Kojima, and J Hokamaki, and H Nakamura, and J Yodoi, and H Ogawa
Placebo-controlled trial of transdermal estrogen therapy alone in postmenopausal women: effects on arterial compliance and endothelial function.
June 2002, Climacteric : the journal of the International Menopause Society,
H Kawano, and H Yasue, and N Hirai, and T Yoshida, and H Fukushima, and S Miyamoto, and S Kojima, and J Hokamaki, and H Nakamura, and J Yodoi, and H Ogawa
Comparison of the effects of transdermal estrogen, oral estrogen, and oral estrogen-progestogen therapy on bone mineral density in postmenopausal women.
January 2002, Journal of bone and mineral metabolism,
Copied contents to your clipboard!